Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/32161
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18034/20233 (89%)
Visitors : 23600878      Online Users : 731
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32161


    Title: Nobiletin Down-Regulates c-KIT Gene Expression and Exerts Antileukemic Effects on Human Acute Myeloid Leukemia Cells
    Authors: Chen, Pei-Yi
    Chen, Yu-Ting
    Gao, Wan-Yun
    Wu, Ming-Jiuan
    Yen, Jui-Hung
    Contributors: Buddhist Tzu Chi Gen Hosp, Ctr Med Genet
    Tzu Chi Univ, Dept Mol Biol & Human Genet
    Chia Nan Univ Pharm & Sci, Dept Biotechnol
    Keywords: nobiletin
    flavonoid
    AML
    c-KIT
    cytarabine
    Date: 2018-12-26
    Issue Date: 2019-11-15 15:43:16 (UTC+8)
    Publisher: AMER CHEMICAL SOC
    Abstract: Nobiletin, a dietary citrus flavonoid, has been reported to possess several biological activities such as antioxidant, anti-inflammatory, and anticancer properties. The aim of this study was to investigate the antileukemic effects of nobiletin and its underlying mechanisms on human acute myeloid leukemia (AML) cells. We demonstrated that nobiletin (0-100 mu M) significantly reduced cell viability from 100.0 +/- 9.6% to 31.1 +/- 2.8% in human AML THP-1 cell line. Nobiletin arrested cell cycle progression in G1 phase and induced myeloid cell differentiation in human AML cells. Microarray analysis showed that mRNA expression of the c-KIT gene, a critical proto-oncogene associated with leukemia progression, was dramatically reduced in nobiletin-treated AML cells. Furthermore, we verified that AML cells treated with nobiletin (40 and 80 mu M) for 48 h markedly suppressed c-KIT mRNA expression (from 1.00 +/- 0.07-fold to 0.62 +/- 0.08- and 0.30 +/- 0.05-fold) and reduced the level of c-KIT protein expression (from 1.00 +/- 0.11-fold to 0.60 +/- 0.15- and 0.34 +/- 0.05-fold) by inhibition of KIT promoter activity. The knockdown of c-KIT expression by shRNA attenuated cancer cell growth and induced cell differentiation. Moreover, we found that the overexpression of c-KIT abolished nobiletin-mediated cell growth inhibition in leukemia cells. These results indicate that nobiletin exerts antileukemic effects through the down-regulation of c-KIT gene expression in AML cells. Finally, we demonstrated that the combination of a conventional AML chemotherapeutic agent, cytarabine, with nobiletin resulted in more reduction of cell viability in AML cells. Our current findings suggest that nobiletin is a novel c-KIT inhibitor and may serve as a chemo-preventive or -therapeutic agent against human AML.
    ???metadata.dc.relation.uri???: http://dx.doi.org/10.1021/acs.jafc.8b05680
    Relation: International Journal of Medicinal Mushrooms, v.66, n.51, pp.13423-13434
    Appears in Collections:[Dept. of Biotechnology (including master's program)] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    10.1021-acs.jafc.8b05680.pdf4272KbAdobe PDF511View/Open
    index.html0KbHTML1117View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback